BIIB
Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 277.55$. Average daily volumn in 3 months 1.74M. Market cap 42.16B
Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD Lastest price : 292.75$. Total volume : 1.44M. Market state PRE Click reload if you want to check the lastest price on market!!!
Biogen Inc. (BIIB)
Last Price
292.75$Change
-6.15Volume
1.44M
| Previous Close | 298.90 |
| Open | 299.18 |
| Day Range | 290.23-299.70 |
| Bid | 285.00 x 800 |
| Ask | 295.50 x 800 |
| Volume | 1.44M |
| Average Volume | 1.74M |
| Market Cap | 42.16B |
| Beta | 0.20 |
| 52 Week Range | 187.16-311.88 |
| Trailing P/E | 14.59 |
| Foward P/E | 18.72 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | N/A |
Financial Details
Organization
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Market Cap:
42.16BRevenue:
10.98BTotal Assets:
23.88BTotal Cash:
2.26B
News about "Biogen Inc."
Biogen shares hit one-year high on new Alzheimer's drug data
Source from : The Business Journals - 6 days ago
The new Alzheimer's disease drug made by Eisai and Biogen is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study, yet was associated with brain bleeds in a significant ...See details»
Biogen Inc.
Source from : Wall Street Journal - 4 days ago
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?
Source from : AOL - 11 days ago
A month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have added about 8.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...See details»
Biogen Inc.'s (NASDAQ:BIIB) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Source from : AOL - 10 days ago
Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 54% over the last three months. We wonder if and what role the company's financials play in that ...See details»
Biogen Stock Is Surging Today: What's Going On?
Source from : Benzinga.com - 6 days ago
Biogen Inc BIIB shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's drug lecanemab. Biogen presented the results from a ...See details»
Biogen shares soar following promising Alzheimer's drug findings
Source from : CNBC on MSN - 6 days ago
CNBC's Jim Cramer and the 'Squawk on the Street' team break down shares of Biogen after the company reported promising trial results for its experimental Alzheimer's drug lecanemab.See details»
Highlights from the Ratings and Financial Report for Biogen Inc. (BIIB)
Source from : newsheater - 6 days ago
Biogen Inc. (NASDAQ:BIIB) went up by 6.46% from its latest closing price compared to the recent 1-year high of $307.53. The company’s stock price has collected -3.39% of loss in the last five trading ...See details»
Research Paper Reports Death in Biogen's Experimental Drug
Source from : SchaeffersResearch.com - 8 days ago
According to the paper, a 65-year-old woman receiving the drug died from a brain hemorrhage Biogen Inc (NASDAQ:BIIB) is under pressure this morning, in the wake of a research paper published on ...See details»
Biogen stock may see pressure after not mentioned in Alzheimer's presentation - analyst
Source from : Seeking Alpha - 6 days ago
Biogen (BIIB) shares may see pressured on Wednesday after the biotech company was never mentioned by name in a 90-minute presentation on Biogen and Eisai's (ESALF) ...See details»
Biogen rallies Alzheimer’s drug developers after full data for lecanemab
Source from : Seeking Alpha - 6 days ago
Biogen (BIIB) shares spiked Wednesday, rallying other Alzheimer's drug developers after the company and its partner Eisai (ESALY) (ESALF) announced full data from their Phase 3 ...See details»
Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates
Source from : Nasdaq - 1 month ago
Biogen Inc. (BIIB) came out with quarterly earnings of $4.77 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.77 per share a year ago.See details»
Biogen Appoints Christopher Viehbacher As President And CEO
Source from : Business Insider - 25 days ago
(RTTNews) - Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of ...See details»
Biogen tops 3Q expectations as cost cutting continues
Source from : Star Tribune - 1 month ago
Analysts expect, on average, earnings of $16.51 for 2022. Shares of Cambridge, Massachusetts-based Biogen Inc. started climbing before markets opened Tuesday.See details»
Biogen hires former Sanofi head Viehbacher as CEO
Source from : Yahoo! Sports - 26 days ago
(Reuters) -Biogen Inc on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the U.S. drugmaker put behind it a series of ...See details»